Affiliation:
1. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
2. Infections and Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany
3. Finnish Cancer Centre-Mid Finland, Tampere, Finland
4. Faculty of Medicine, University of Oulu, Oulu, Finland
5. European Science Infrastructure Services, Oulu, Finland
6. Clinical Pathology/Cytology, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden
Abstract
Abstract
Background
Human papillomaviruses (HPV) cause several human cancers. Bivalent (Cervarix) and quadrivalent (qGardasil) HPV vaccines both contain virus-like particles of the major oncogenic HPV types 16 and 18, but also cross-protect against some nonvaccine types. However, data on long-term sustainability of the cross-reactive antibody responses to HPV vaccines are scarce.
Methods
Serum samples donated 7–12 years after immunization at age 16–17 years with bivalent (n = 730) or quadrivalent (n = 337) HPV vaccine were retrieved from the population-based Finnish Maternity Cohort biobank. Serum antibody levels against HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73 were determined using multiplex pseudovirion binding assay. Antibody avidity was assessed using ammonium thiocyanate treatment.
Results
Seropositivity for HPV31, 33, 35, 45, 51, 52, 58, 59, 68, and 73 was increasingly common (P ≤ .001; χ 2 test for trend for each of these types) when women had high anti-HPV16 antibody levels. For 8 nonvaccine HPV types seropositivity was more common among recipients of bivalent than quadrivalent vaccine, in particular for HPV31, 35, 45, 51, 52, and 58 (P < .001). Antibody avidity was higher in the quadrivalent vaccine recipients for HPV6, 11, and two of the nonvaccine types, but lower for HPV16 and 18 (P < .001).
Conclusions
Both vaccines elicit cross-reactive antibodies detectable even 12 years after vaccination. Cross-reactive seropositivity is more common in women with high anti-HPV16 antibody response and in the bivalent vaccine recipients.
Funder
Swedish Cancer Society
Swedish Foundation for Strategic Research
Academy of Finland
Karolinska Institutet
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Immunology and Allergy